MariTide
About
About MariTide
MariTide (AMG 133) is a GIP receptor antagonist / GLP-1 receptor agonist fusion molecule developed by Amgen with a monthly dosing interval — the longest injection interval of any obesity therapeutic in development. Phase II data showed 20% weight loss at 52 weeks. Its monthly convenience and potent efficacy position it as a potential market disruptor if Phase III results confirm Phase II findings.
Science
Mechanism of Action
Simultaneously blocks GIP receptors (antagonism, unlike tirzepatide's agonism) and activates GLP-1 receptors; the GIP antagonism enhances GLP-1-mediated weight loss through incompletely understood mechanisms involving adipose tissue and CNS receptor cross-talk.
Dosing
Typical Protocol
Monthly subcutaneous injection; Phase II dose range not disclosed; Phase III initiated 2024.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
No verified providers offering MariTide yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering MariTide.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.